TIL-based ACT regimes show promise in a range of solid cancers

The combination of adoptive cell therapy (ACT) with tumour infiltrating lymphocytes (TIL) and checkpoint inhibitors (CPI) appear to show promise in heavily pretreated patients with a range of solid cancers. A Danish study, published in the Journal for Immunotherapy of Cancer, comprised 25 adults with metastatic disease across 10 solid cancer types including colon cancer ...

Already a member?

Login to keep reading.

© 2021 the limbic